Combined first-trimester screening for preterm small-for-gestational-age infants: Australian multicenter clinical feasibility study.

Ultrasound Obstet Gynecol

Discipline of Obstetrics, Gynaecology and Neonatology, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.

Published: January 2025

Objective: To assess the performance of the Fetal Medicine Foundation (FMF) first-trimester competing-risks screening model for small-for-gestational-age (SGA) fetuses requiring delivery at < 37 weeks' gestation, in a large cohort of women receiving maternity care in Australia.

Methods: This was a retrospective analysis of prospectively collected data from a cohort of women attending one of two private multicenter fetal medicine practices for first-trimester screening for preterm pre-eclampsia (PE), defined as PE requiring delivery before 37 weeks' gestation. Risk for preterm SGA, defined as SGA requiring delivery before 37 weeks, was calculated but was not disclosed to the patient or referring physician. Screening data were matched to obstetric outcomes. The primary outcome was the efficacy of the FMF screening model in assessing the risk of preterm SGA. The potential effect on identifying other adverse pregnancy outcomes was also assessed.

Results: During the study period, 22 841 women with a singleton pregnancy underwent combined first-trimester screening for preterm PE. These data were compared with those of 301 721 women in the state of Victoria with a singleton pregnancy who did not undergo screening during the study period. Calculation of the risk for preterm SGA identified 3030 (13.3%) pregnancies as high risk. The sensitivity of the model was 48.6% (95% CI, 41.0-56.2%), specificity was 87.0% (95% CI, 86.6-87.5%) and positive and negative predictive values were 2.9% (95% CI, 2.7-3.1%) and 99.5% (95% CI, 99.4-99.6%) respectively. Pregnancies at high risk for preterm SGA were also more likely to have preterm PE (risk ratio (RR), 2.28 (95% CI, 1.72-3.03)) and preterm birth (RR, 1.46 (95% CI, 1.32-1.63)), compared with unscreened pregnancies. Pregnancies at low risk for preterm SGA were less likely to result in a stillbirth (RR, 0.64 (95% CI, 0.47-0.86)) compared with unscreened pregnancies.

Conclusion: Combined first-trimester screening for preterm SGA shows moderate screening efficacy and therefore could help to inform pregnancy management and improve antenatal resource allocation. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.

Download full-text PDF

Source
http://dx.doi.org/10.1002/uog.29174DOI Listing

Publication Analysis

Top Keywords

combined first-trimester
4
first-trimester screening
4
screening preterm
4
preterm small-for-gestational-age
4
small-for-gestational-age infants
4
infants australian
4
australian multicenter
4
multicenter clinical
4
clinical feasibility
4
feasibility study
4

Similar Publications

Objective: To investigate the predictive value of soluble FMS-like tyrosine kinase-1 (sFlt-1), coagulation function, and platelet (PLT) parameters for preeclampsia (PE).

Methods: A prospective study was conducted on women registered and delivered at XXXX Hospital from October 2020 to December 2021. All eligible pregnant women were recruited at the time of initial registration in the first trimester.

View Article and Find Full Text PDF

First trimester cervical angles for the prediction of spontaneous preterm birth.

Eur J Obstet Gynecol Reprod Biol

January 2025

Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong SAR, China; Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong SAR, China. Electronic address:

Objective: First trimester cervical angles for the prediction of spontaneous preterm birth (sPTB) remains unclear. The objective is to explore the potential value of first trimester cervical angles for the prediction of sPTB.

Study Design: This was a secondary analysis of data derived from a prospective cohort study for sPTB screening in singleton pregnancies at 11 + 0-13 + 6 weeks in women attending routine Down's syndrome screening at Prince of Wales Hospital, Hong Kong SAR, between June 2018 and July 2020.

View Article and Find Full Text PDF

The immune landscape of fetal chorionic villous tissue in term placenta.

Front Immunol

January 2025

Department of Microbiology, Immunology and Molecular Genetics, University of Kentucky, Lexington, KY, United States.

Introduction: The immune compartment within fetal chorionic villi is comprised of fetal Hofbauer cells (HBC) and invading placenta-associated maternal monocytes and macrophages (PAMM). Recent studies have characterized the transcriptional profile of the first trimester (T1) placenta; however, the phenotypic and functional diversity of chorionic villous immune cells at term (T3) remain poorly understood.

Methods: To address this knowledge gap, immune cells from human chorionic villous tissues obtained from full-term, uncomplicated pregnancies were deeply phenotyped using a combination of flow cytometry, single-cell RNA sequencing (scRNA-seq, CITE-seq) and chromatin accessibility profiling (snATAC-seq).

View Article and Find Full Text PDF

Background: Noninvasive prenatal diagnosis (NIPD) has been proven feasible for non-syndromic hearing loss (NSHL) in singleton pregnancies. However, previous research is limited to the second trimester and the application in twin pregnancies is blank. Here we provide a novel algorithmic approach to assess singleton and twin pregnancies in the first trimester.

View Article and Find Full Text PDF

Maternal cell-free DNA in early pregnancy for preeclampsia screening: a systematic review.

Arch Gynecol Obstet

January 2025

Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.

Purpose: To quantify the separation between maternal blood cell-free (cf)DNA markers in preeclampsia and unaffected pregnancies and compare with existing markers. This approach has not been used in previous studies.

Methods: Comprehensive systematic literature search of PubMed to identify studies measuring total cfDNA, fetal cf(f)DNA or the fetal fraction (FF) in pregnant women.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!